Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Number of Sales Reps in 43 Pharmas Dwindles by 4,906 in 4 Years: Survey
September 28, 2018
- Daiichi Sankyo Begins PIII Breast Cancer Trials for DS-8201
September 27, 2018
- IBM Japan Joins Takeda’s Shonan iPark
September 27, 2018
- Celgene Seeks Japan OK for Pomalyst Triplet for MM
September 27, 2018
- Alunbrig Outstrips Xalkori in Front-Line ALK NSCLC, Cuts Disease Progression or Death Risks by 51%: Takeda
September 27, 2018
- I/O in Lung Cancer - 6: Analyst Says US Merck Claimed Victory in 2018 ASCO Confab, Applauds Trial Designs for Keytruda
September 26, 2018
- Takeda’s Brigatinib Snags European Panel OK for 2nd Line ALK-Positive NSCLC
September 26, 2018
- Xtandi Gets CHMP Backing for Additional CRPC Indication
September 26, 2018
- DS-8201 Shows Positive PI Study Data for NSCLC: Daiichi Sankyo
September 26, 2018
- European Panel Backs Approval of Kyowa Kirin’s Mogamulizumab for Mycosis Fungoides, Sézary Syndrome
September 26, 2018
- Santen Files for Japan Approval of Anti-Allergy Eye Drop
September 26, 2018
- Daiichi Sankyo, Pfizer Grab Japan Approval for Herceptin Biosimilars
September 25, 2018
- AMED Backs Project for Development of Familial Adenomatous Polyposis Therapy Applied by FunPep, 3 Universities
September 25, 2018
- Fujifilm Kyowa Kirin, Mylan Bag EU Approval of Humira Biosimilar
September 25, 2018
- Daiichi Sankyo Teams Up with US Merck’s Subsidiary for Clinical Research of DS-8201/Keytruda Combo
September 25, 2018
- Astellas to Create New Business beyond Core Prescription Drug Business, Aims to Launch Several Products by FY2020
September 21, 2018
- Meiji Seika Pharma Commences Shipment of KM Biologics’ Flu Vaccine
September 21, 2018
- Roxadustat Hit Goal in CKD Patients with Anemia Not on Dialysis in Multinational PIII Study: Astellas
September 21, 2018
- Meiji Files Aricept Generic for Lewy Body Dementia to Win Full Indications
September 21, 2018
- Growing Number of Drug Makers Introducing LGBT-Friendly Policies
September 20, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…